This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Accelrys Offers Novel, Integrated Predictive Sciences Solutions Enabling Faster, More Cost-effective Innovation For Life Sciences Organizations

LONDON, Sept. 25, 2013 /PRNewswire/ --  Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, has announced the availability of an extensive set of advanced predictive sciences applications and services. These integrated capabilities enable drug discovery teams to investigate and evaluate hypotheses about the chemical or biological behavior of molecules of therapeutic interest in silico prior to costly experimentation. Accelrys predictive sciences leverages the open, scientifically aware Accelrys Enterprise Platform to deliver an advanced scientific decision support environment that reduces time and expense, improves quality, enhances collaboration and accelerates innovation in bringing new drugs to market.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/62190-accelrys-offers-integrated-predictive-sciences-solutions-faster-innovation

(Photo: http://photos.prnewswire.com/prnh/20130925/MM85145) (Logo: http://photos.prnewswire.com/prnh/20120416/MM88629LOGO)

"The complexity of today's science means that many organizations lack the experimental resources to test for every biologically relevant endpoint for all compounds of interest," said Adel Laoui, Ph.D., MBA, managing director of the Accelrys Life Sciences R&D segment. "On the other hand, the breadth and accuracy of predictive sciences are now mature enough to facilitate resolution of a broad range of R&D challenges using less expensive and more scalable in silico methodologies. This enables scientists to evaluate many more hypotheses more quickly than is possible with experiment alone, enhancing the speed of decision making. By combining a workflow-based approach with new informatics predictive modeling tools and high quality experimental data, Accelrys predictive sciences enables R&D groups to build, publish and consume in silico models in a social, collaborative environment."   

Faced with looming "patent cliffs" and increasing pressure to demonstrate positive health outcomes with reduced operating costs, many life sciences R&D organizations are restructuring into smaller and more agile teams to improve productivity.  To remain competitive, research teams are also externalizing many discovery processes and leveraging advanced predictive solutions to accelerate the identification and testing of small molecules or biologics with favorable properties. Drug discovery is a multi-objective optimization process with drug researchers striving to improve all properties or criteria simultaneously. As a result, predictive science methods for modeling multiple properties such as biochemical potency, in vivo pharmacokinetics and formulations are now routinely delivered and shared across all phases of R&D.

To support this paradigm shift in life sciences R&D and align with today's market trends, the latest 4.0 release of Accelrys Discovery Studio supports scientific exploration from early-stage target identification through lead identification and optimization to preclinical safety testing.  Discovery Studio 4.0 features new biotherapeutics science to identify mutation sites for disulfide bridges, enabling molecular biologists and antibody engineers to improve the stability of novel biologics. The latest release also includes enhancements to both scalability and performance in long-duration (nanosecond) simulations and fully re-engineered non-bond interaction analysis, accelerating structure-based drug design in small molecules research.

Taking advantage of the integrated Accelrys Enterprise Platform, medicinal, synthetic and computational chemists, molecular biologists and computational structural biologists can leverage the following Accelrys predictive sciences solutions for improved end-to-end information management and decision support across the enterprise and networked external partners.

To learn more about Accelrys predictive sciences, register for the complimentary webinar to be held on Thursday, October 17, 8-9 a.m. PDT entitled "Major Transformations within the Pharmaceutical Industry and an Overview of Accelrys Predictive Sciences." 

About Accelrys, Inc. Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management solutions, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad and flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, California, USA, Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com.

SOURCE Accelrys, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,172.68 -107.06 -0.62%
S&P 500 1,994.29 -16.11 -0.80%
NASDAQ 4,527.6890 -52.10 -1.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs